Daniel Swinson

Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial

Hugo Ford, Andrea Marshall, John Bridgewater et al. · The Lancet Oncology · 2013 · 604 citations · Full text

Public Health, Community Health, Communities Of Practice +14

First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials

Harpreet Wasan, Navesh Sharma, Volker Heinemann et al. · The Lancet Oncology · 2017 · 398 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer

Peter S Hall, Daniel Swinson, David A. Cairns et al. · JAMA Oncology · 2021 · 191 citations · Full text

Medicine, Geriatric Medicine, Oncology +14

Tumour necrosis is an independent prognostic marker in non-small cell lung cancer: correlation with biological variables

Daniel Swinson, J. Louise Jones, Donna Richardson et al. · Lung Cancer · 2002 · 187 citations

Medicine, Oncology, Pathology +14

Hypoxia-inducible factor-1 alpha in non small cell lung cancer: relation to growth factor, protease and apoptosis pathways.

Daniel Swinson, J. Louise Jones, G. Cox et al. · PubMed · 2004 · 152 citations

Medicine, Cancer Biology, Oncology +16